Physician
Mary Hitchcock Memorial Hospital
Mary Hitchcock Memorial Hospital was paid $32.31M by Medicaid between Jan 2018 and Dec 2024, across 540 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 18% of everything it billed.
33Billing provider infoMARY HITCHCOCK MEMORIAL HOSPITAL
LEBANON, NH 03756
LEBANON, NH 03756
33aNPI1023092053assigned 12/02/2005
33bProvider typeInternal Medicine Physician
28Total paid$32.31M
24GClaims1,291,441
24DCodes billed540
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Internal Medicine Physician providers in New Hampshire
Rank by total paid#1 of 34
Median peer was paid$13K
This provider vs. median2,422×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 244,485 | $5.44M | |
| 2019 | 294,002 | $6.12M | |
| 2020 | 214,933 | $4.75M | |
| 2021 | 213,845 | $5.37M | |
| 2022 | 211,544 | $5.58M | |
| 2023 | 72,580 | $2.97M | |
| 2024incomplete | 40,052 | $2.08M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 18% | 105,611 | 88,140 | $5.76M |
| A0431 | Ambulance service, conventional air services, transport, one way (rotary wing) | 8.9% | 1,760 | 1,220 | $2.87M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 6.2% | 50,195 | 43,699 | $2.01M |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 2.9% | 13,179 | 11,287 | $925K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.8% | 3,939 | 3,113 | $891K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.5% | 5,199 | 4,091 | $817K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 2.3% | 1,744 | 1,419 | $741K |
| G0378 | Hospital observation service, per hour | 2.2% | 5,487 | 2,105 | $713K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.0% | 1,776 | 1,470 | $644K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.9% | 12,973 | 11,320 | $625K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.8% | 6,327 | 5,851 | $592K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 1.5% | 361 | 248 | $489K |
528 more codes
| 70551 | Magnetic resonance imaging, brain; without contrast material | 1.3% | 1,098 | $433K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.3% | 46,734 | $424K |
| 99203 | Doctor's office visit, new patient (routine) | 1.3% | 7,630 | $417K |
| A0436 | Rotary wing air mileage, per statute mile | 1.3% | 587 | $408K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.1% | 5,191 | $370K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.1% | 10,093 | $344K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 1.0% | 1,296 | $325K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 31,230 | $306K |
| 80053 | Comprehensive metabolic panel | <1% | 48,058 | $304K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 8,132 | $291K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 1,220 | $288K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,214 | $274K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 7,157 | $273K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 60,375 | $266K |
| 99283 | Emergency room visit (moderate) | <1% | 2,086 | $255K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 12,400 | $255K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 12,371 | $252K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,161 | $238K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 11,647 | $226K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,246 | $202K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,435 | $194K |
| 80061 | Lipid panel | <1% | 18,475 | $184K |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 57 | $179K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,078 | $170K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 7,209 | $163K |
| 87631 | <1% | 2,387 | $154K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 6,247 | $145K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,523 | $144K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 2,350 | $141K |
| 92060 | <1% | 4,159 | $135K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,016 | $124K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 832 | $123K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,178 | $118K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 17,528 | $117K |
| 81229 | <1% | 410 | $111K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,974 | $107K |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 1,332 | $106K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 675 | $99K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 4,420 | $91K |
| 99205 | Prolong outpt/office vis | <1% | 822 | $91K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 494 | $90K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,144 | $87K |
| 99243 | <1% | 1,232 | $86K | |
| 76770 | <1% | 927 | $86K | |
| J2704 | Injection, propofol, 10 mg | <1% | 9,483 | $85K |
| 82728 | <1% | 8,982 | $84K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 18,515 | $84K |
| 96112 | <1% | 1,027 | $79K | |
| 92567 | <1% | 8,152 | $77K | |
| 84439 | <1% | 11,930 | $76K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 4,189 | $75K |
| 93325 | <1% | 888 | $70K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,352 | $69K |
| 86003 | <1% | 1,595 | $69K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 5,711 | $68K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 6,836 | $67K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 879 | $66K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 874 | $63K |
| 86803 | <1% | 6,083 | $63K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 1,478 | $62K |
| 87522 | Neg quan hep c or qual rna | <1% | 1,863 | $61K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 970 | $60K |
| 83970 | <1% | 2,553 | $59K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 236 | $57K |
| 84702 | <1% | 4,790 | $55K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 729 | $55K |
| 87536 | <1% | 1,307 | $55K | |
| 96415 | <1% | 1,398 | $54K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 11,841 | $54K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 730 | $53K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 123 | $52K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,072 | $52K |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 3,454 | $52K |
| 86480 | <1% | 1,179 | $50K | |
| 82607 | <1% | 6,407 | $50K | |
| 82784 | <1% | 6,066 | $50K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 110,412 | $49K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 794 | $49K |
| 94010 | <1% | 1,805 | $49K | |
| 86780 | <1% | 4,924 | $48K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,755 | $48K |
| 83516 | <1% | 4,802 | $47K | |
| 83550 | <1% | 7,636 | $45K | |
| 92015 | Determination of refractive state | <1% | 4,961 | $44K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 583 | $44K |
| 87070 | <1% | 6,517 | $44K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 62 | $44K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,796 | $43K |
| 72141 | <1% | 129 | $43K | |
| 86850 | <1% | 5,413 | $43K | |
| 80076 | <1% | 8,154 | $43K | |
| 64615 | <1% | 740 | $42K | |
| 85027 | <1% | 8,789 | $42K | |
| 84403 | <1% | 2,236 | $41K | |
| 92582 | <1% | 1,049 | $41K | |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 543 | $41K |
| 86235 | <1% | 603 | $39K | |
| 73560 | <1% | 744 | $39K | |
| 88341 | <1% | 745 | $39K | |
| 87340 | <1% | 5,323 | $38K | |
| 83655 | <1% | 3,678 | $38K | |
| 87077 | <1% | 5,288 | $36K | |
| 99245 | <1% | 348 | $36K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 921 | $34K |
| 83540 | <1% | 7,772 | $34K | |
| 71250 | <1% | 253 | $33K | |
| D7210 | Extraction, erupted tooth requiring removal of bone and/or sectioning of tooth | <1% | 519 | $31K |
| 31231 | <1% | 424 | $31K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,229 | $30K |
| 73610 | <1% | 736 | $30K | |
| 82746 | <1% | 3,058 | $30K | |
| 80050 | General health panel | <1% | 3,938 | $29K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 982 | $29K |
| 93017 | <1% | 299 | $28K | |
| 87186 | <1% | 4,435 | $28K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 3,759 | $28K |
| 86140 | <1% | 7,980 | $27K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 93 | $27K |
| 95816 | <1% | 196 | $27K | |
| 93000 | <1% | 1,962 | $27K | |
| 92134 | <1% | 3,334 | $26K | |
| 92556 | <1% | 1,088 | $26K | |
| 83880 | <1% | 1,815 | $26K | |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 382 | $26K |
| 92083 | <1% | 1,096 | $25K | |
| 73030 | <1% | 722 | $25K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 1,065 | $25K |
| 73630 | <1% | 602 | $25K | |
| 91120 | <1% | 113 | $24K | |
| 86762 | <1% | 2,383 | $24K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 1,361 | $24K |
| 86618 | <1% | 2,262 | $24K | |
| 74183 | <1% | 65 | $24K | |
| 82670 | <1% | 1,045 | $22K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 318 | $22K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 479 | $22K |
| 86706 | <1% | 2,801 | $22K | |
| 82105 | <1% | 1,804 | $22K | |
| 74018 | <1% | 411 | $21K | |
| 94729 | <1% | 518 | $21K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 57 | $21K |
| 82570 | <1% | 5,535 | $21K | |
| 83735 | <1% | 5,560 | $21K | |
| 88342 | <1% | 1,933 | $20K | |
| 99152 | <1% | 1,500 | $20K | |
| 81001 | <1% | 9,305 | $20K | |
| 90686 | <1% | 4,493 | $20K | |
| 90837 | Psychotherapy session, about an hour | <1% | 539 | $19K |
| 97162 | <1% | 738 | $19K | |
| 93226 | <1% | 220 | $18K | |
| 83001 | <1% | 1,258 | $18K | |
| 83690 | <1% | 4,242 | $18K | |
| 85610 | <1% | 7,847 | $18K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 499 | $17K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 4,966 | $17K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 93 | $17K |
| 84146 | <1% | 1,120 | $17K | |
| 91322 | <1% | 128 | $17K | |
| 72100 | <1% | 305 | $17K | |
| 96411 | <1% | 237 | $16K | |
| 93321 | <1% | 413 | $16K | |
| 84402 | <1% | 911 | $16K | |
| 96376 | <1% | 735 | $16K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 373 | $16K |
| A0425 | Ground mileage, per statute mile | <1% | 62 | $16K |
| 85652 | <1% | 8,430 | $16K | |
| 71045 | Radiologic examination, chest; single view | <1% | 441 | $16K |
| 73110 | <1% | 358 | $16K | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 344 | $15K |
| 82043 | <1% | 4,036 | $15K | |
| 86038 | <1% | 1,822 | $15K | |
| 73130 | <1% | 310 | $15K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 1,323 | $15K |
| 87899 | <1% | 1,476 | $15K | |
| 83993 | <1% | 775 | $15K | |
| 92504 | <1% | 1,051 | $15K | |
| 87905 | <1% | 1,266 | $14K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,541 | $14K |
| D7240 | Removal of impacted tooth - completely bony | <1% | 351 | $14K |
| 83002 | <1% | 958 | $14K | |
| 97803 | <1% | 436 | $14K | |
| 95811 | <1% | 79 | $14K | |
| 87147 | <1% | 2,192 | $13K | |
| 20610 | <1% | 295 | $13K | |
| 86704 | <1% | 1,558 | $13K | |
| C1769 | Guide wire | <1% | 1,403 | $13K |
| 84153 | <1% | 1,288 | $13K | |
| 88307 | <1% | 507 | $13K | |
| 92250 | <1% | 890 | $12K | |
| 96111 | <1% | 263 | $12K | |
| 73502 | <1% | 407 | $12K | |
| 83520 | <1% | 1,225 | $12K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 192 | $12K |
| 84484 | <1% | 2,124 | $11K | |
| 95953 | <1% | 38 | $11K | |
| 81329 | <1% | 463 | $11K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 70 | $11K |
| 82565 | <1% | 3,645 | $10K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 12,576 | $10K |
| 86376 | <1% | 989 | $10K | |
| 86900 | <1% | 5,436 | $10K | |
| 82950 | <1% | 2,840 | $10K | |
| 96417 | <1% | 334 | $10K | |
| 76830 | Ultrasound, transvaginal | <1% | 121 | $10K |
| 99417 | Prolong home eval add 15m | <1% | 123 | $10K |
| 86901 | <1% | 5,436 | $10K | |
| 87081 | <1% | 2,183 | $10K | |
| 95117 | <1% | 1,082 | $10K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,239 | $10K |
| 84305 | <1% | 746 | $10K | |
| 85730 | <1% | 2,847 | $10K | |
| 82977 | <1% | 1,813 | $9K | |
| 86708 | <1% | 1,068 | $9K | |
| 93296 | <1% | 726 | $9K | |
| 83615 | <1% | 3,222 | $9K | |
| 97161 | <1% | 490 | $9K | |
| 82962 | <1% | 5,681 | $9K | |
| 84100 | <1% | 3,890 | $9K | |
| J0185 | Injection, aprepitant, 1 mg | <1% | 103 | $9K |
| 86160 | <1% | 678 | $9K | |
| 91122 | <1% | 113 | $9K | |
| 86255 | <1% | 727 | $9K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,021 | $9K |
| 84165 | <1% | 1,209 | $9K | |
| 80164 | <1% | 1,028 | $9K | |
| 17110 | <1% | 167 | $9K | |
| 59025 | Fetal non-stress test | <1% | 188 | $8K |
| 86225 | <1% | 838 | $8K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 71 | $8K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 10,855 | $8K |
| 82274 | <1% | 753 | $8K | |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or qualified healthcare professional, with or without direct patient contact (list separately in addition to cpt codes 99205, 99215, 99483 for office or other outpatient evaluation and management services) (do not report g2212 on the same date of service as 99358, 99359, 99415, 99416). (do not report g2212 for any time unit less than 15 minutes) | <1% | 417 | $8K |
| 81003 | <1% | 6,527 | $8K | |
| 76942 | <1% | 103 | $8K | |
| 91200 | <1% | 549 | $8K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 690 | $8K |
| 84480 | <1% | 794 | $8K | |
| 96119 | <1% | 86 | $8K | |
| 84460 | <1% | 2,159 | $8K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 58 | $8K |
| 82533 | <1% | 604 | $8K | |
| 99001 | <1% | 1,719 | $8K | |
| 87205 | <1% | 2,438 | $7K | |
| 86039 | <1% | 898 | $7K | |
| 87102 | <1% | 1,259 | $7K | |
| 86787 | <1% | 818 | $7K | |
| 84156 | <1% | 3,030 | $7K | |
| 81025 | <1% | 1,717 | $7K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 325 | $7K |
| 84163 | <1% | 577 | $7K | |
| 93922 | <1% | 198 | $7K | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 2,657 | $7K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 80 | $6K |
| 70355 | <1% | 395 | $6K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 6,170 | $6K |
| 81401 | <1% | 379 | $6K | |
| 84450 | <1% | 1,689 | $6K | |
| 92579 | <1% | 238 | $6K | |
| 82550 | <1% | 1,502 | $6K | |
| 86800 | <1% | 649 | $6K | |
| 72040 | <1% | 160 | $6K | |
| 86200 | <1% | 629 | $6K | |
| 88304 | <1% | 335 | $6K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 74 | $6K |
| 86431 | <1% | 1,409 | $6K | |
| 82803 | <1% | 483 | $6K | |
| 85018 | <1% | 3,144 | $6K | |
| 73522 | <1% | 91 | $6K | |
| 84550 | <1% | 2,181 | $6K | |
| 82247 | <1% | 1,702 | $6K | |
| 96132 | <1% | 105 | $5K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 9,652 | $5K |
| 92557 | <1% | 207 | $5K | |
| 72082 | <1% | 76 | $5K | |
| 83883 | <1% | 837 | $5K | |
| 96139 | <1% | 44 | $5K | |
| 86696 | <1% | 355 | $5K | |
| 77336 | <1% | 85 | $5K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 2,515 | $5K |
| 81002 | <1% | 2,036 | $5K | |
| 82677 | <1% | 266 | $5K | |
| 87902 | <1% | 81 | $5K | |
| 64405 | <1% | 160 | $5K | |
| 82040 | <1% | 2,103 | $5K | |
| 82248 | <1% | 1,448 | $5K | |
| 82947 | <1% | 1,817 | $5K | |
| 84425 | <1% | 320 | $5K | |
| A0434 | Specialty care transport (sct) | <1% | 14 | $5K |
| 82310 | <1% | 1,505 | $4K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 96 | $4K |
| 84481 | <1% | 357 | $4K | |
| 98940 | <1% | 274 | $4K | |
| 98941 | Chiropractic manipulative treatment; spinal, 3-4 regions | <1% | 232 | $4K |
| 85046 | <1% | 1,864 | $4K | |
| 84520 | <1% | 1,737 | $4K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 464 | $4K |
| 96133 | <1% | 37 | $4K | |
| 31575 | <1% | 84 | $4K | |
| 91010 | <1% | 48 | $4K | |
| 72146 | <1% | 17 | $4K | |
| 80175 | <1% | 590 | $4K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 31 | $4K |
| 82627 | <1% | 202 | $4K | |
| 86695 | <1% | 355 | $4K | |
| 86359 | <1% | 450 | $3K | |
| 87046 | <1% | 512 | $3K | |
| 87045 | <1% | 500 | $3K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 108 | $3K |
| 77002 | <1% | 116 | $3K | |
| 83718 | <1% | 589 | $3K | |
| 82150 | <1% | 793 | $3K | |
| 83010 | <1% | 384 | $3K | |
| 86336 | <1% | 269 | $3K | |
| 88185 | <1% | 29 | $3K | |
| 80177 | <1% | 436 | $3K | |
| 82785 | <1% | 244 | $3K | |
| 85379 | <1% | 477 | $3K | |
| 84075 | <1% | 978 | $3K | |
| J0475 | Injection, baclofen, 10 mg | <1% | 16 | $3K |
| 83721 | <1% | 783 | $3K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,389 | $3K |
| 0071A | <1% | 139 | $3K | |
| 96409 | <1% | 37 | $3K | |
| 0072A | <1% | 135 | $3K | |
| 87328 | <1% | 284 | $3K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,429 | $3K |
| 84590 | <1% | 321 | $3K | |
| 90480 | <1% | 169 | $3K | |
| 91038 | <1% | 20 | $3K | |
| 84630 | <1% | 351 | $3K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 15 | $3K |
| 83498 | <1% | 121 | $3K | |
| 70486 | <1% | 15 | $3K | |
| 87040 | <1% | 312 | $3K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 232 | $3K |
| 87075 | <1% | 366 | $3K | |
| 86308 | <1% | 590 | $3K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,785 | $2K |
| 96138 | <1% | 90 | $2K | |
| 86361 | <1% | 329 | $2K | |
| 87329 | <1% | 318 | $2K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 119 | $2K |
| 85014 | <1% | 1,338 | $2K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,512 | $2K |
| 91065 | <1% | 58 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,433 | $2K |
| 82378 | <1% | 171 | $2K | |
| 86769 | <1% | 65 | $2K | |
| 76499 | <1% | 174 | $2K | |
| 73552 | <1% | 46 | $2K | |
| 87206 | <1% | 503 | $2K | |
| 0124A | <1% | 97 | $2K | |
| 93971 | <1% | 32 | $2K | |
| 17311 | <1% | 23 | $2K | |
| 90461 | <1% | 109 | $2K | |
| 86665 | <1% | 85 | $2K | |
| 80069 | <1% | 277 | $2K | |
| 99242 | <1% | 42 | $2K | |
| 0134A | <1% | 90 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,283 | $2K |
| 82131 | <1% | 223 | $2K | |
| 96118 | <1% | 17 | $2K | |
| 95700 | <1% | 13 | $2K | |
| 82172 | <1% | 133 | $2K | |
| 88312 | <1% | 91 | $2K | |
| 81243 | <1% | 31 | $2K | |
| 87486 | <1% | 70 | $2K | |
| 87581 | <1% | 70 | $2K | |
| 84132 | <1% | 898 | $2K | |
| 87015 | <1% | 445 | $2K | |
| 82465 | <1% | 668 | $2K | |
| C1893 | Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, other than peel-away | <1% | 169 | $2K |
| 84155 | <1% | 797 | $2K | |
| 69210 | <1% | 70 | $2K | |
| 91037 | <1% | 43 | $2K | |
| 82951 | <1% | 160 | $2K | |
| 87529 | <1% | 43 | $2K | |
| 89051 | <1% | 589 | $2K | |
| 84295 | <1% | 779 | $2K | |
| Q3014 | Telehealth originating site facility fee | <1% | 1,078 | $2K |
| 90656 | <1% | 374 | $2K | |
| 99495 | <1% | 16 | $2K | |
| 97802 | <1% | 39 | $2K | |
| 97163 | <1% | 28 | $1K | |
| 0074A | <1% | 77 | $1K | |
| 82435 | <1% | 733 | $1K | |
| D7230 | <1% | 25 | $1K | |
| 90846 | Family psychotherapy without the patient present, 50 minutes | <1% | 25 | $1K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,329 | $1K |
| 82542 | <1% | 115 | $1K | |
| 0064A | <1% | 52 | $1K | |
| 83605 | <1% | 233 | $1K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 124 | $1K |
| 80197 | <1% | 388 | $1K | |
| 95874 | <1% | 130 | $1K | |
| 64642 | <1% | 12 | $1K | |
| 0054A | <1% | 58 | $1K | |
| 82390 | <1% | 139 | $1K | |
| 96367 | <1% | 34 | $1K | |
| 92133 | <1% | 74 | $1K | |
| 74019 | <1% | 17 | $1K | |
| 83630 | <1% | 95 | $1K | |
| 90717 | <1% | 13 | $1K | |
| 88184 | <1% | 34 | $994.29 | |
| 86664 | <1% | 85 | $984.27 | |
| 82374 | <1% | 499 | $961.24 | |
| 82657 | <1% | 56 | $948.26 | |
| 0001A | <1% | 31 | $941.10 | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 14 | $929.40 |
| J3490 | Unclassified drugs | <1% | 2,782 | $892.80 |
| 92225 | <1% | 123 | $888.78 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 31 | $888.76 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 34 | $869.40 |
| 99407 | <1% | 55 | $858.61 | |
| G0127 | Trimming of dystrophic nails, any number | <1% | 101 | $811.84 |
| T1023 | Screening to determine the appropriateness of consideration of an individual for participation in a specified program, project or treatment protocol, per encounter | <1% | 27 | $796.82 |
| 95251 | <1% | 82 | $794.85 | |
| 0004A | <1% | 39 | $789.42 | |
| 72081 | <1% | 13 | $780.48 | |
| 80081 | <1% | 16 | $767.30 | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 42 | $764.24 |
| C1729 | Catheter, drainage | <1% | 54 | $753.85 |
| 80051 | <1% | 145 | $753.64 | |
| 86022 | <1% | 51 | $727.94 | |
| 83525 | <1% | 86 | $713.60 | |
| 51798 | <1% | 98 | $702.21 | |
| 96167 | <1% | 15 | $688.73 | |
| 88321 | <1% | 34 | $676.44 | |
| 92552 | <1% | 38 | $634.43 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 15 | $624.38 |
| 80055 | <1% | 54 | $615.56 | |
| 0052A | <1% | 29 | $605.72 | |
| 92226 | <1% | 129 | $574.87 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 42 | $566.95 |
| 82340 | <1% | 163 | $552.44 | |
| 83521 | <1% | 26 | $552.00 | |
| 84445 | <1% | 12 | $535.77 | |
| 0154A | <1% | 26 | $532.61 | |
| 82140 | <1% | 65 | $519.14 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 191 | $518.76 |
| 86364 | <1% | 12 | $515.08 | |
| 92551 | <1% | 79 | $512.97 | |
| 87338 | <1% | 57 | $505.86 | |
| 87449 | <1% | 64 | $502.30 | |
| 82952 | <1% | 160 | $501.35 | |
| 87324 | <1% | 61 | $492.35 | |
| 62370 | <1% | 18 | $486.03 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 171 | $468.95 |
| 84478 | <1% | 113 | $464.53 | |
| 84436 | <1% | 150 | $464.52 | |
| 73590 | <1% | 15 | $441.19 | |
| 92202 | <1% | 122 | $414.29 | |
| 82103 | <1% | 44 | $409.45 | |
| 83020 | <1% | 40 | $407.66 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 731 | $405.85 |
| 99442 | <1% | 68 | $400.68 | |
| 92526 | <1% | 12 | $400.46 | |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 12 | $393.75 |
| 96156 | <1% | 32 | $391.57 | |
| 95886 | <1% | 19 | $388.37 | |
| 94664 | <1% | 40 | $373.31 | |
| 86341 | <1% | 12 | $366.80 | |
| 84134 | <1% | 54 | $361.68 | |
| 96127 | <1% | 136 | $346.27 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,130 | $342.95 |
| 88313 | <1% | 46 | $323.98 | |
| 81479 | Unlisted molecular pathology procedure | <1% | 12 | $321.94 |
| 82525 | <1% | 28 | $286.98 | |
| 99443 | <1% | 28 | $256.30 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 189 | $251.72 |
| 0111A | <1% | 13 | $248.46 | |
| 99188 | <1% | 33 | $230.12 | |
| 85240 | <1% | 14 | $218.05 | |
| 99173 | <1% | 79 | $207.62 | |
| 0081A | <1% | 13 | $197.38 | |
| 83789 | <1% | 14 | $196.69 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 63 | $187.06 |
| 94760 | <1% | 76 | $184.39 | |
| G0008 | Administration of influenza virus vaccine | <1% | 602 | $182.95 |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 38 | $180.34 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 69 | $164.65 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 73 | $164.44 |
| 88173 | <1% | 14 | $163.97 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 112 | $146.31 |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 13 | $132.80 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 145 | $119.19 |
| 84446 | <1% | 13 | $118.85 | |
| 85049 | <1% | 53 | $103.13 | |
| 90653 | <1% | 47 | $81.65 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 56 | $78.02 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 73 | $74.50 |
| 97012 | <1% | 16 | $68.89 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 31 | $66.68 |
| 84300 | <1% | 18 | $59.40 | |
| 99201 | <1% | 27 | $44.06 | |
| 82945 | <1% | 19 | $44.00 | |
| 84157 | <1% | 19 | $40.56 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 55 | $35.97 |
| C9257 | Injection, bevacizumab, 0.25 mg | <1% | 32 | $31.14 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 42 | $28.92 |
| 99411 | <1% | 17 | $25.15 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 20 | $22.35 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 75 | $21.38 |
| 81000 | <1% | 12 | $14.94 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 17 | $9.10 |
| C1758 | Catheter, ureteral | <1% | 16 | $6.16 |
| 91307 | <1% | 393 | $1.72 | |
| 91305 | <1% | 175 | $0.92 | |
| 91312 | <1% | 97 | $0.65 | |
| 91313 | <1% | 90 | $0.59 | |
| 91300 | <1% | 126 | $0.55 | |
| 91308 | <1% | 69 | $0.35 | |
| 91306 | <1% | 51 | $0.25 | |
| 91311 | <1% | 28 | $0.18 | |
| 91315 | <1% | 26 | $0.17 | |
| 90694 | 0% | 12 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 46 | $0.00 |
| 96040 | 0% | 117 | $0.00 | |
| 90698 | 0% | 55 | $0.00 | |
| 90697 | 0% | 12 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 289 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 965 | $0.00 |
| 90670 | 0% | 69 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 18 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 295 | $0.00 |
| 90662 | 0% | 43 | $0.00 | |
| 80364 | 0% | 24 | $0.00 | |
| 90633 | 0% | 27 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJANTZEN, DANIEL (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Dartmouth-Hitchcock Clinic | Lebanon, NH | $31.39M |
| Dartmouth-Hitchcock Clinic | Keene, NH | $606K |
| Dartmouth-Hitchcock Clinic | Lebanon, NH | $93K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.